{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:33Z","timestamp":1791925413474,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["smrv-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine Reviews"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.smrv.2016.09.004","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T01:03:22Z","timestamp":1477616602000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-7108","authenticated-orcid":false,"given":"Akira","family":"Kuriyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smrv.2016.09.004_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.sleep.2005.08.008","article-title":"Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors","volume":"7","author":"Morin","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"Ohayon","year":"2002","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.smrv.2016.09.004_bib3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.sleep.2009.07.008","article-title":"Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD)","volume":"10","author":"Ohayon","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib4","first-page":"S7","article-title":"Insomnia: definition, prevalence, etiology, and consequences","volume":"3","author":"Roth","year":"2007","journal-title":"J\u00a0Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/hr.2013.70","article-title":"The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies","volume":"36","author":"Meng","year":"2013","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"key":"10.1016\/j.smrv.2016.09.004_bib6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijcard.2014.07.284","article-title":"Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies","volume":"176","author":"Li","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.smrv.2016.09.004_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","article-title":"Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies","volume":"135","author":"Baglioni","year":"2011","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.smrv.2016.09.004_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smrv.2011.03.008","article-title":"Insomnia and daytime cognitive performance: a meta-analysis","volume":"16","author":"Fortier-Brochu","year":"2012","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.smrv.2016.09.004_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/CIRCULATIONAHA.113.004500","article-title":"Association between insomnia symptoms and mortality: a prospective study of U.S. men","volume":"129","author":"Li","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.smrv.2016.09.004_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.5665\/SLEEP.1230","article-title":"Insomnia and the performance of US workers: results from the America insomnia survey","volume":"34","author":"Kessler","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2016.09.004_bib11","first-page":"1","article-title":"Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians","author":"Wilt","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/M15-2175","article-title":"Clinical guidelines committee of the American College of P. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib13","first-page":"487","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J\u00a0Clin sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib14","first-page":"225","article-title":"Meta-analysis of benzodiazepine use in the treatment of insomnia","volume":"162","author":"Holbrook","year":"2000","journal-title":"CMAJ Can Med Assoc J J Assoc Med Can"},{"key":"10.1016\/j.smrv.2016.09.004_bib15","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1001\/jama.1997.03550240060035","article-title":"Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy","volume":"278","author":"Nowell","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.smrv.2016.09.004_bib16","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11606-007-0251-z","article-title":"The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs","volume":"22","author":"Buscemi","year":"2007","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib17","first-page":"e8343","article-title":"Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration","volume":"345","author":"Huedo-Medina","year":"2012","journal-title":"BMJ (Clinical Research ed)"},{"key":"10.1016\/j.smrv.2016.09.004_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1525-1497.2005.0243.x","article-title":"The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis","volume":"20","author":"Buscemi","year":"2005","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib19","doi-asserted-by":"crossref","first-page":"e63773","DOI":"10.1371\/journal.pone.0063773","article-title":"Meta-analysis: melatonin for the treatment of primary sleep disorders","volume":"8","author":"Ferracioli-Oda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.smrv.2016.09.004_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.sleep.2013.11.788","article-title":"Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis","volume":"15","author":"Kuriyama","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.smrv.2014.06.001","article-title":"Doxepin for insomnia: a systematic review of randomized placebo-controlled trials","volume":"19","author":"Yeung","year":"2015","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.smrv.2016.09.004_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2042098615595359","article-title":"Suvorexant in insomnia: efficacy, safety and place in therapy","volume":"6","author":"Rhyne","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.smrv.2016.09.004_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-Month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.smrv.2016.09.004_bib24","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.smrv.2016.09.004_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.smrv.2016.09.004_bib26","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib27","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.smrv.2016.09.004_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib30","unstructured":"US Food and Drug Administration. http:\/\/www.fda.gov\/[Last access as of May 18, 2016.]."},{"key":"10.1016\/j.smrv.2016.09.004_bib31","unstructured":"Pharmaceutical and Medical Devices Agency. https:\/\/www.pmda.go.jp [Last access as of May 18, 2016.]."},{"key":"10.1016\/j.smrv.2016.09.004_bib32","doi-asserted-by":"crossref","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","article-title":"A\u00a0comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.smrv.2016.09.004_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.smrv.2016.09.004_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/sim.4780070807","article-title":"A\u00a0note on graphical presentation of estimated odds ratios from several clinical trials","volume":"7","author":"Galbraith","year":"1988","journal-title":"Statistics Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Res ed)"},{"key":"10.1016\/j.smrv.2016.09.004_bib36","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","article-title":"Suvorexant: first global approval","volume":"74","author":"Yang","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.smrv.2016.09.004_bib37","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-Road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2016.09.004_bib38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/jcph.523","article-title":"Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects","volume":"55","author":"Uemura","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.smrv.2016.09.004_bib39","first-page":"9","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J\u00a0Clin sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.rmed.2014.12.010","article-title":"Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease","volume":"109","author":"Sun","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.smrv.2016.09.004_bib41","unstructured":"Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, et\u00a0al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia."},{"key":"10.1016\/j.smrv.2016.09.004_bib42","unstructured":"Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep\/wakefulness states in mice."},{"key":"10.1016\/j.smrv.2016.09.004_bib43","unstructured":"Hoyer D, Durst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, et\u00a0al. Distinct effects of IPSU and suvorexant on mouse sleep architecture."}],"container-title":["Sleep Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108707921630096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108707921630096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T01:51:59Z","timestamp":1536285119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108707921630096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":43,"alternative-id":["S108707921630096X"],"URL":"https:\/\/doi.org\/10.1016\/j.smrv.2016.09.004","relation":{},"ISSN":["1087-0792"],"issn-type":[{"value":"1087-0792","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smrv.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}